{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-26-000051","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2026-08-07T20:04:16+00:00","discovered_at":"2026-08-07T20:05:10.259990+00:00","generated_at":"2026-08-07T20:05:21.556078+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"aTyr Pharma restructures: 60% workforce cut, CFO change, $58.9M cash, Phase 3 protocol pending FDA","bullets":["Workforce reduction of ~60% and annualized opex savings of ~$13M starting Q4 2026.","CFO Jill Broadfoot steps down Sept 30, 2026; Brandon Yaras becomes CFO Oct 1, 2026.","Q2 2026 cash $58.9M; runway into late 2028; R&D $6.7M, G&A $4.1M.","Phase 3 protocol for efzofitimod in pulmonary sarcoidosis submitted to FDA June 2026; feedback expected by end of August 2026.","Phase 2 EFZO-CONNECT in SSc-ILD enrollment completed; topline results expected Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-26-000051","json":"https://secwatch.observer/filing/0001339970-26-000051.json","markdown":"https://secwatch.observer/filing/0001339970-26-000051.md","text":"https://secwatch.observer/filing/0001339970-26-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/0001339970-26-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T20:05:21.556078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}